Arvinas

New Capabilities

Receives $50M milestone; co-developer of first approved PROTAC

For 25 years, drug companies have tried to design medicines that don't just block harmful proteins but destroy them outright. On May 1, the U.S. Food and Drug Administration (FDA) approved the first one. VEPPANU, developed by biotech Arvinas and Pfizer, treats a hard-to-treat form of metastatic breast cancer by hijacking the cell's own garbage-disposal system to shred a mutated estrogen receptor that fuels the tumor.

Updated Yesterday